Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium phosphate. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium phosphate. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium phosphate. |
| Cisatracurium | The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium phosphate. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium phosphate. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium phosphate. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium phosphate. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium phosphate. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium phosphate. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium phosphate. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium phosphate. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium phosphate. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium phosphate. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium phosphate. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium phosphate. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium phosphate. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium phosphate. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium phosphate. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium phosphate. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Magnesium phosphate. |
| Cyclosporine | The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium phosphate. |
| Doxycycline | The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Magnesium phosphate. |
| Lymecycline | The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium phosphate. |
| Capreomycin | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium phosphate. |
| Piperacillin | The risk or severity of neuromuscular blockade can be increased when Piperacillin is combined with Magnesium phosphate. |
| Framycetin | The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Magnesium phosphate. |
| Clomocycline | The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Magnesium phosphate. |
| Quinine | The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium phosphate. |
| Vancomycin | The risk or severity of neuromuscular blockade can be increased when Vancomycin is combined with Magnesium phosphate. |
| Tigecycline | The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Magnesium phosphate. |
| Oxytetracycline | The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Magnesium phosphate. |
| Chloroquine | The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Magnesium phosphate. |
| Demeclocycline | The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Magnesium phosphate. |
| Magnesium sulfate | The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Magnesium phosphate. |
| Tobramycin | The risk or severity of neuromuscular blockade can be increased when Tobramycin is combined with Magnesium phosphate. |
| Tetracycline | The risk or severity of neuromuscular blockade can be increased when Tetracycline is combined with Magnesium phosphate. |
| Gentamicin | The risk or severity of neuromuscular blockade can be increased when Gentamicin is combined with Magnesium phosphate. |
| Etacrynic acid | The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium phosphate. |
| Quinidine | The risk or severity of neuromuscular blockade can be increased when Quinidine is combined with Magnesium phosphate. |
| Metacycline | The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Magnesium phosphate. |
| Netilmicin | The risk or severity of neuromuscular blockade can be increased when Netilmicin is combined with Magnesium phosphate. |
| Neomycin | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium phosphate. |
| Minocycline | The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium phosphate. |
| Procainamide | The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium phosphate. |
| Streptomycin | The risk or severity of neuromuscular blockade can be increased when Streptomycin is combined with Magnesium phosphate. |
| Colistimethate | The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Magnesium phosphate. |
| Kanamycin | The risk or severity of neuromuscular blockade can be increased when Kanamycin is combined with Magnesium phosphate. |
| Clindamycin | The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Magnesium phosphate. |
| Dantrolene | The risk or severity of neuromuscular blockade can be increased when Dantrolene is combined with Magnesium phosphate. |
| Rolitetracycline | The risk or severity of neuromuscular blockade can be increased when Rolitetracycline is combined with Magnesium phosphate. |
| Magnesium oxide | The risk or severity of neuromuscular blockade can be increased when Magnesium oxide is combined with Magnesium phosphate. |
| Magnesium cation | The risk or severity of neuromuscular blockade can be increased when Magnesium cation is combined with Magnesium phosphate. |
| Paromomycin | The risk or severity of neuromuscular blockade can be increased when Paromomycin is combined with Magnesium phosphate. |
| Lincomycin | The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium phosphate. |
| Ribostamycin | The risk or severity of neuromuscular blockade can be increased when Ribostamycin is combined with Magnesium phosphate. |
| Geneticin | The risk or severity of neuromuscular blockade can be increased when Geneticin is combined with Magnesium phosphate. |
| Apramycin | The risk or severity of neuromuscular blockade can be increased when Apramycin is combined with Magnesium phosphate. |
| Gentamicin C1a | The risk or severity of neuromuscular blockade can be increased when Gentamicin C1a is combined with Magnesium phosphate. |
| Neamine | The risk or severity of neuromuscular blockade can be increased when Neamine is combined with Magnesium phosphate. |
| Arbekacin | The risk or severity of neuromuscular blockade can be increased when Arbekacin is combined with Magnesium phosphate. |
| Viomycin | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium phosphate. |
| Puromycin | The risk or severity of neuromuscular blockade can be increased when Puromycin is combined with Magnesium phosphate. |
| Magnesium hydroxide | The risk or severity of neuromuscular blockade can be increased when Magnesium hydroxide is combined with Magnesium phosphate. |
| Magnesium trisilicate | The risk or severity of neuromuscular blockade can be increased when Magnesium trisilicate is combined with Magnesium phosphate. |
| Magnesium chloride | The risk or severity of neuromuscular blockade can be increased when Magnesium chloride is combined with Magnesium phosphate. |
| Magnesium acetate tetrahydrate | The risk or severity of neuromuscular blockade can be increased when Magnesium acetate tetrahydrate is combined with Magnesium phosphate. |
| Magnesium carbonate | The risk or severity of neuromuscular blockade can be increased when Magnesium carbonate is combined with Magnesium phosphate. |
| Magnesium citrate | The risk or severity of neuromuscular blockade can be increased when Magnesium citrate is combined with Magnesium phosphate. |
| Magnesium glycinate | The risk or severity of neuromuscular blockade can be increased when Magnesium glycinate is combined with Magnesium phosphate. |
| Magnesium Aluminum Silicate | The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium phosphate. |
| Dihydrostreptomycin | The risk or severity of neuromuscular blockade can be increased when Dihydrostreptomycin is combined with Magnesium phosphate. |
| Hygromycin B | The risk or severity of neuromuscular blockade can be increased when Hygromycin B is combined with Magnesium phosphate. |
| Sisomicin | The risk or severity of neuromuscular blockade can be increased when Sisomicin is combined with Magnesium phosphate. |
| Plazomicin | The risk or severity of neuromuscular blockade can be increased when Plazomicin is combined with Magnesium phosphate. |
| Magnesium silicate | The risk or severity of neuromuscular blockade can be increased when Magnesium silicate is combined with Magnesium phosphate. |
| Penimepicycline | The risk or severity of neuromuscular blockade can be increased when Penimepicycline is combined with Magnesium phosphate. |
| Magnesium aspartate | The risk or severity of neuromuscular blockade can be increased when Magnesium aspartate is combined with Magnesium phosphate. |
| Isepamicin | The risk or severity of neuromuscular blockade can be increased when Isepamicin is combined with Magnesium phosphate. |
| Magnesium gluconate | The risk or severity of neuromuscular blockade can be increased when Magnesium gluconate is combined with Magnesium phosphate. |
| Magnesium orotate | The risk or severity of neuromuscular blockade can be increased when Magnesium orotate is combined with Magnesium phosphate. |
| Magnesium acetate | The risk or severity of neuromuscular blockade can be increased when Magnesium phosphate is combined with Magnesium acetate. |
| Magnesium stearate | The risk or severity of neuromuscular blockade can be increased when Magnesium phosphate is combined with Magnesium stearate. |
| Colistin | The risk or severity of neuromuscular blockade can be increased when Colistin is combined with Magnesium phosphate. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum toxin type B. |
| Botulinum toxin type A | The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium phosphate. |
| Nicotine | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Nicotine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Mecamylamine. |
| Pentolinium | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Trimethaphan. |
| Hexamethonium | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Hexamethonium. |
| Cyclopentamine | The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Cyclopentamine. |
| LetibotulinumtoxinA | The therapeutic efficacy of Letibotulinumtoxina can be increased when used in combination with Magnesium phosphate. |
| DaxibotulinumtoxinA | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium phosphate. |